Cetyl Myristoleate
Description
Cetyl Myristoleate (CM) is an ester of the fatty acid myristoleic acid (cis-9-tetradecenoic acid).
It is present in the oil glands of male beavers and in mice. It was discovered, by Dr. Harry Diehl at the National Institutes of Health, as the factor which gives the Swiss Albino mouse its immunity to bacterial arthritis.
Method of Action
Supplemental forms of CM are derived from beef fat in reaction with cetyl alcohol. Both components appear to increase lubrication and resilience of joint cartilage and other tissues.
CM may also inhibit hte lipoxygenase pathway of leucotriene production from arachadonic acid. Leucotrienes are involved in pro-inflammatory activities, including broncho- and vaso- constriction.
One leucotriene (B 4) attracts white blood cells which may attack the tissues in an auto-immune reaction.
Therapeutic Approaches
CM may be indicated as a dietary supplement for inflammatory conditions, including:
bursitis, fibromyalgia, irritable bowel syndrome, osteoarthritis, prostatitis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis.
CM is not indicated for the acute stage of inflammation, following trauma, however, it may support tissues which are prone to develop arthritis, following such trauma e.g. whiplash.
CM may be combined with flax seed oil, or Evening Primrose Oil, for nutritional support of autoimmune reactions.
Dosage
Softgel capsules: 2 or 3 capsules daily, split between breakfast and dinner. (260 mg)
Liquid: 600 - 1,000 mg daily, split between breakfast and dinner.
Powder: 4 - 7 gm daily (600 - 1,000 mg elemental CM), split between breakfast and dinner.
A topical cream is also being developed, in liposomal form, which will be able to enter the joints via the skin.
Toxicity Factors
No toxicity or contra-indications have been noted.
If gastric upset occurs, decrease the amount and try taking it with lecithin and a glass of water to aid digestion.
References
Diehl, H. & May, E.L. : Cetyl myristoleate isolated from Swiss Albino mice: an apparent protective agent against adjuvant arthritis in rats. J of Pharm. Sciencees 1994, 83(3): 296-299.
Siemandi, H.S. : The effect of cis-9-Cetyl myristoleate and adjunctive therapy on the course of arthritis episodes in patients with various auto-immune diseases characterized by the common terminology, "Arthritis" and "Psoriasis". A randomized clinical trial, 431 patients. Submitted. 1997.
| Signup Free Applied Health Journal |
||||
|
FREE Sample Issue Your email address is all we need to start you on a better path to health. We respect your privacy.
|
